![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Prime Medicine
Main focus: Prime editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases: Undisclosed
Genome editing tool: Prime editing
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://primemedicine.com/
Gene editing partnerships: Beam Therapeutics
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_prime_medicine_logo_approved_Color_Logo_b97151309f_0dca42365b.jpg)
Prime Medicine is a start-up company that focuses on prime editing. Prime editing is a novel CRISPR-derived gene-editing technology, which was first disclosed in October 2019. Although the company has not revealed its first pre-clinical candidate, it launched with $315M in combined Series A and B funding. The company is co-founded by Professor David R. Liu, who also co-founded Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics.